Tag: Dr. William O’Neill


New Data from NCSI Demonstrates 72% Survival with 98% Native Heart Recovery

New data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients from 35 sites demonstrates 72% survival with 98% native heart recovery at discharge. The patients were treated with the NCSI protocol, which includes placing the Impella heart pump before revascularization. The study demonstrates the protocol-based approach to … Continue reading “New Data from NCSI Demonstrates 72% Survival with 98% Native Heart Recovery”

Dr. Bill O’Neill explains the concept of cardioprotection

What is Cardioprotection? Dr. Bill O’Neill of Henry Ford Health System and co-principle investigator of the FDA STEMI-DTU safety and feasibility RCT, discusses the concept of cardioprotection. Cardioprotection is a cellular response to protect the myocardium from suffering irreversible injury.   IMP-449 Subscribe, or join the conversation by following us on Twitter: @ProtectedPCI

National Cardiogenic Shock Initiative: 1 Year Later

Video Chapters: The Impact of The Cardiogenic Shock Initiative (NCSI): One Year Later William O’Neill, MD Advances in the Treatment of Cardiovascular Disease in Women: PCI, MI, Shock, Myocarditis, SCAD, and Post-partum Cardiomyopathy Cindy Grines, MD Understanding the Importance of Ventricular Unloading in Management of AMI and Cardiogenic Shock Navin Kapur, MD Subscribe, or join the … Continue reading “National Cardiogenic Shock Initiative: 1 Year Later”

Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device

Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) database. The clinical publication highlights best practice protocols based on real-world evidence that is showing improved outcomes in cardiogenic shock. This clinical evidence is derived from Abiomed’s observational , commercial IQ database. In patients with AMICS receiving … Continue reading “Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device”

Protected PCI: Current Data and Best Practices in High-Risk Patients

In this roundtable discussion, Dr. John Lasala of Washington University in St. Louis interviews Dr. Bill O’Neill (Henry Ford Hospital, Detroit, MI), Dr. Bill Lombardi (University of Washington, Seattle, WA), and Dr. Jeff Moses (Columbia University, New York, NY) on the current data regarding high-risk patients undergoing Protected PCI. During this interview, Dr. Moses provides … Continue reading “Protected PCI: Current Data and Best Practices in High-Risk Patients”

Hemodynamic Benefits of Impella RP® Heart Pump for Right Heart Failure

Dr. William O’Neill and Dr. Mark Anderson, co-principle investigators of the RECOVER-RIGHT clinical trial, and Dr. Seth Bilazarian discuss the hemodynamic benefits of using the Impella RP® heart pump for right heart failure. The Impella RP® is the first and only percutaneous heart pump approved by the FDA as safe and effective for acute right … Continue reading “Hemodynamic Benefits of Impella RP® Heart Pump for Right Heart Failure”

Dr. Bill O’Neill Discusses Recovery Time from RV and LV Shock with Impella RP® Support

In this physician Q&A session, Dr. Bill O’Neill discusses recovery considerations as well as time to recovery following Impella RP® support for right ventricular (RV) and left ventricular shock. In this video, Dr. O’Neill also describes the rapid recovery (<24 hours) of patients with acute myocardial infarction receiving the Impella RP®. In addition, Dr. O’Neill … Continue reading “Dr. Bill O’Neill Discusses Recovery Time from RV and LV Shock with Impella RP® Support”

IMPRESS in Severe Shock Trial: Looking Closer at the Data

For patients with cardiogenic shock (CS), intra-aortic balloon pump (IABP) had been an important tool for maintaining patients and improving survival after percutaneous coronary intervention (PCI). Randomized controlled trials, however, have found very little evidence to support the notion that IABP is helpful for reducing mortality or improving hemodynamics for patients with CS.1,2 The Impella® … Continue reading “IMPRESS in Severe Shock Trial: Looking Closer at the Data”